Literature DB >> 14005656

Treatment of endotoxic shock--the dilemma of vasopressor and vasodilator therapy.

M H WEIL, R B SUDRANN, H SHUBIN.   

Abstract

Hemodynamic studies have demonstrated that the fall of blood pressure in shock caused by endotoxin in dogs does not result primarily from dilatation or "vasomotor collapse." Indeed, vasoconstriction is increased and may be excessive. Progression of shock has recently been blamed on such excessive vasoconstriction. For this reason the use of sympathomimetic drugs as vasopressor agents has been challenged and sympatholytic or adrenolytic agents have been recommended. In the present study, vasopressor and vasodilator drugs were used for the treatment of shock in dogs caused by endotoxin. Vasodilator drugs, when used after the onset of shock, hastened a fatal outcome but vasopressor agents were not detrimental when used in moderate doses. The effectiveness of the vasopressor agent is not necessarily due to a primary vasoconstrictor action on arteries and arterioles, as previously assumed.

Entities:  

Keywords:  SHOCK/experimental; TOXINS AND ANTITOXINS; VASODILATOR AGENTS/pharmacology; VASOPRESSIN/pharmacology

Mesh:

Substances:

Year:  1962        PMID: 14005656      PMCID: PMC1574840     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  8 in total

1.  Experimental studies on therapy of circulatory failure produced by endotoxin.

Authors:  M H WEIL; B S MILLER
Journal:  J Lab Clin Med       Date:  1961-05

2.  Physiological approach to successful treatment of endotoxin shock in the experimental animal.

Authors:  R C LILLEHEI; L D MACLEAN
Journal:  AMA Arch Surg       Date:  1959-03

3.  The intestinal factor in irreversible endotoxin shock.

Authors:  R C LILLEHEI; L D MACLEAN
Journal:  Ann Surg       Date:  1958-10       Impact factor: 12.969

4.  Studies on the circulatory changes in the dog produced by endotoxin from gram-negative microorganisms.

Authors:  L D MACLEAN; W W SPINK; M B VISSCHER; M H WEIL
Journal:  J Clin Invest       Date:  1956-11       Impact factor: 14.808

5.  Hemodynamic effects of vasopressor agent (metaraminol) on hypotension in dogs produced by endotoxin.

Authors:  L B HINSHAW; L D MACLEAN; W W SPINK; M B VISSCHER; M H WEIL
Journal:  Proc Soc Exp Biol Med       Date:  1956-07

6.  Canine intestinal and liver weight changes induced by E. coli endotoxin.

Authors:  L D MACLEAN; W W SPINK; M B VISSCHER; M H WEIL
Journal:  Proc Soc Exp Biol Med       Date:  1956-07

7.  Hypotension (shock) in dogs produced by Escherichia coli endotoxin.

Authors:  L D MACLEAN; M H WEIL
Journal:  Circ Res       Date:  1956-09       Impact factor: 17.367

8.  The relationship between the vascular manifestations of shock produced by endotoxin, trauma, and hemorrhage. I. Certain similarities between the reactions in normal and endotoxin-tolerant rats.

Authors:  B W ZWEIFACH; L THOMAS
Journal:  J Exp Med       Date:  1957-09-01       Impact factor: 14.307

  8 in total
  5 in total

1.  HDFx: a novel biologic immunomodulator is therapeutically -effective in hemorrhagic and intestinal-ischemic shock: importance of microcirculatory-immunological interactions and their potential implications for the warfighter and disaster victims.

Authors:  Burton M Altura; Anthony Carella; Asefa Gebrewold
Journal:  Int J Clin Exp Med       Date:  2011-11-09

2.  ENDOTOXIN SHOCK IN THE PRIMATE: TREATMENT WITH PHENOXYBENZAMINE.

Authors:  J A VICK
Journal:  J Clin Invest       Date:  1964-02       Impact factor: 14.808

3.  Small intestinal blood flow.

Authors:  E C TEXTER
Journal:  Am J Dig Dis       Date:  1963-07

Review 4.  Is there a place for proteinase inhibition? A review of the literature.

Authors:  G D Lister
Journal:  Postgrad Med J       Date:  1969-08       Impact factor: 2.401

5.  Nitroglycerin reverts clinical manifestations of poor peripheral perfusion in patients with circulatory shock.

Authors:  Alexandre Lima; Michel E van Genderen; Jasper van Bommel; Eva Klijn; Tim Jansem; Jan Bakker
Journal:  Crit Care       Date:  2014-06-19       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.